High expression level of miR-1260 family in the peripheral blood of patients with ovarian carcinoma

Abstract

The most common gynecologic cancers detected in women in Turkey are uterine cancer, ovarian cancer, and cervical cancer. These data reported that a mean of 3800 individuals were diagnosed with uterine cancer, 2790 were diagnosed with ovarian cancer, and 1950 were diagnosed with cervical cancer, and 400 individuals were diagnosed with other gynecologic cancers each year in Turkey. A mean of 14.270 individuals were detected to have been diagnosed with gynecologic cancers each year in the United States of America (USA). Ovarian cancer treatment is generally composed of chemotherapy, and surgery. In general, chemotherapy is administered after surgery. The identification of the molecular pathogenesis of ovarian cancer, and discovery of new moleculer biomarkers which facilitate the ovarian cancer treatment are required for an effective ovarian cancer treatment in clinics. miRNAs are reported to be the possible biologic indicators for various cancer types. We aimed to investigate 2 miRNAs which were suggested to have effect in ovarian cancer in our (previous) monozygotic twin study from miR-1260 microRNA family whose association with ovarian cancer yet has not been reported in the literature. We investigated the expression levels of miR-1260a, and miR-1260b miRNAs, in the peripheral blood lymphocytes of 150 familial and sporadic ovarian cancer patients, and of 100 healthy individuals of the control group who were matched for age, sex, and ethnicity with the patient group, and investigated their possible property of being a biologic indicator for ovarian cancer. The expression results of ovarian cancer patients were evaluated by comparison of the results of the control group in the study. The expression levels of miR-1260a, and miR-1260b in ovarian cancer patients were found highly increased compared with the levels in the control group. miR-1260a expression level in ovarian cancer patients was detected to have increased approximately 17 fold compared with the control group, and miR-1260b expression level in ovarian cancer patients was detected to have increased approximately 33 fold compared with the levels in the control group. The String Analyses showed that the miR-1260a was associated with the ribosomal protein family which was known to be effective in the translation stage of cell and that miR-1260b was associated with CHEK2 protein which was a member of the serine/threonine-protein kinase family. It should be investigated for larger cohorts in benign ovarian diseases and in different stages of patients receiving ovarian cancer treatment whether these two molecules are a noninvasive biomarker and therapeutic target to be used especially in the early diagnosis and prognosis of ovarian cancer in future.

Plasma MicroRNAs Related to Metabolic Syndrome in Mexican Women

“…The expression of hsa-miR-1260a has been reported in smooth muscle cells [53], monocyte-derived dendritic cells [54], and in the circulation of subjects infected with the virus A influenza [55]. This c-miRNA has also been related to malignant diseases, such as breast cancer [56, 57], prostate cancer [58], melanoma [59], ovarian carcinoma [60], lung adenocarcinoma [61], and asthma [62]. According to a recent review by Fodor et al [63], miRNAs dysregulated in the MetS may have effects on tumor signaling pathways.…”

MicroRNA expression associated with low-grade cervical intraepithelial neoplasia outcomes

“…Conversely, miR-1260a was upregulated in women with LGCIN that progressed. Upregulation of miR-1260a has been linked to many cancers including cancers of the sex organs (ovarian cancer in women and prostate cancer in men) (Ghafour et al 2021 ; Said et al 2018 ), and based on studies of the closely related miRNA miR-1260b, may promote invasion/metastasis (Morita et al 2020 ; Xu et al 2018 ). The dysregulation of miR-638 and miR-1260a at the early stages of cervical dysplasia may facilitate advancement to high-grade cervical dysplasia by causing dysregulation of pathways involved in oncogenesis.…”

Comparison of Serum and Urine as Sources of miRNA Markers for the Detection of Ovarian Cancer

“…et al [ 14 ]. Ghafour et al [ 15 ] described miR-1260a as a diagnostic biomarker in blood for ovarian cancer.…”

“…It was shown that compared to healthy controls, miR-92a and miR-200b were upregulated in cancer patients [ 17 ]. Zhou et al [ 15 ] examined urine samples from patients with serous ovarian adenocarcinoma and found that miR-30a-5p was upregulated compared to healthy controls. This finding also correlated with tumor stage and lymph node invasion.…”